A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience
A systematic review of antiandrogens and feminization in transgender women
Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial
Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents
Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial
Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series
Gonadotropin Releasing Hormone (GnRH) Agonist Therapy Induces a Sustained Reduction in Plasma Testosterone Levels and Is Well Tolerated in Transwomen Veterans
Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study
Very Low-dose Cyproterone Acetate (12.5 Mg/day) Is Effective As Androgen Blocker; Well Tolerated And Not Associated With Hypertension Development In Young Female Transgender People